Women with previous gestational diabetes are in high risk of developing T2D within a recent time range after their pregnancy with gestational diabetes. We investigate early metabolic changes prior to T2D and the effect of liraglutide treatment in these high risk individuals.
GDM-TREAT is a 5 year randomized, placebo-controlled trial. The first year was double-blinded the study has been open label for the continuing 4 years.
Primary outcome for the project is to investigate the impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus.
Secondary outcomes are evaluation of the incretin effect, liver status, body composition, cardiovascular biomarkers, gut microbiota, oxidative stress, bone mineral density, quality of life, appetite and incretin hormones in the treatment group, placebo group and in a group of healthy women without history of previous gestational diabetes.
Last patient last visit is expected in august 2019.
To investigate the effect of the glucagon-like peptide-1 receptor agonist liraglutide on pathophysiological characteristics and the risk of type 2 diabetes mellitus in women with previous gestational diabetes mellitus.
Elisabeth R. Mathiesen and Peter Damm, Center for pregnant women with diabetes, Rigshospitalet. Jens A. Svare, Department of Gynaecology and obstetrics, Herlev Gentofte Hospital. Tine D. Clausen and Birgit Bødker, Department of Gynaecology and obstetrics, Nordsjællands Hospital. Charlotte Strandberg and Peter M. Gørtz, Department of X-ray and scanning, Herlev Gentofte Hospital. Jens Juul Holst, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Nicklas R. Jørgensen, Department of Clinical Biochemistry, Rigshospitalet Glostrup. Henning Grønbeck, Medical hepato- gastroenterologic department, Aarhus University Hospital
LinksFoghsgaard S, Vedtofte L, Mathiesen ER, et al. BMJ Open 2013;3:e003834. doi:10.1136/bmjopen-2013-003834
Foghsgaard S et al. Diabetologia (2017) 60:1344–1353. DOI 10.1007/s00125-017-4265-8
Foghsgaard et al. Diabetes Care 2017;40:109–116 | DOI: 10.2337/dc16-1017